Are you tired of those small brown spots that appear on your skin as you age? Well, it's time to get familiar with the term "lentigo." Lentigo is a common skin condition that affects many people worldwide. It can be harmless or indicative of more severe conditions such as cancer. But don't worry! In this blog post, we'll cover everything you need to know about lentigo so that you can understand what causes it, how to prevent it and treat it effectively.
Lentigo is a common skin condition that is characterized by dark patches on the skin. The patches may be small or large, and they can appear on any part of the body. While lentigo is not harmful, it can be a cosmetic concern for some people. There are several treatment options available for those who wish to lighten the dark patches.
There are two main types of lentigo: acquired and congenital. Acquired lentigo is the most common type, and it can be caused by sun exposure, aging, or certain medications. Congenital lentigo is a much rarer type that's present at birth.
Sun exposure is the most common cause of acquired lentigo. The ultraviolet (UV) radiation in sunlight can damage the DNA in skin cells, which can lead to the development of abnormal pigment cells. This type of damage is more likely to occur in people who have lighter skin, as they have less melanin to protect them from UV radiation.
Aging is another common cause of acquired lentigo. As we age, our skin becomes thinner and less able to repair itself after damage. This makes us more susceptible to developing lentigo from sun exposure or other sources of skin damage.
Certain medications can also cause acquired lentigo. These include certain antipsychotic drugs, anti-seizure medications, and chemotherapy drugs. People who take these medications may develop lentigo on any area of their body that's exposed to the sun.
People of all ages and skin types can develop lentigo, but it is most common in those who are fair-skinned or have a history of sun exposure. Those who have freckles or moles are also at increased risk.
Lentigo is a common skin condition that can affect people of all ages. The most common symptom of lentigo is a small, dark spot on the skin. These spots are usually harmless and do not cause any pain or discomfort. However, in some cases, lentigo can be a sign of a more serious underlying medical condition. If you have any concerns about your skin, it is important to see a dermatologist for an evaluation.
There is no cure for lentigo, but the condition can be managed. Treatment options include:
-Avoiding sun exposure and using sunscreen when outdoors
-Moisturizing the skin regularly
-Using topical retinoids to help fade the spots
-Having regular laser or light therapy treatments
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation